Pfizer, Inc.

PFE

US7170811035

Pharmaceuticals

Market Closed - Nyse Other stock markets 01:31:20 17/07/2024 am IST			After market 04:30:10 am
29.5 ^USD	+1.37%		29.5	0.00%

15/07	Everest Medicines Announces Positive Topline Results from Maintenance Period of Etrasimod Phase 3 Clinical Trial Conducted in Asia for the Treatment of Moderately-to-Severely Active Ulcerative Colitis	CI
12/07	Health Care Up as Momentum Builds -- Health Care Roundup	DJ

Pfizer : Dubai Steps Up Rollout Of The Pfizer Jab

January 05, 2021 at 07:40 pm IST

We have a big focus on vaccines, as Dubai steps up rollout of the Pfizer jab.

self

BSA Ahmad Bin Hezeem & Associates LLP
BSA Ahmad Bin Hezeem & Associates LLP
Level 6, Building 3, The Gate Precinct
Dubai International Financial Centre
PO Box 262
Dubai
UNITED ARAB EMIRATES
Tel: 43685555
Fax: 43685000
E-mail: nour.eltal@bsabh.com
URL: www.bsabh.com

Latest news about Pfizer, Inc.

Everest Medicines Announces Positive Topline Results from Maintenance Period of Etrasimod Phase 3 Clinical Trial Conducted in Asia for the Treatment of Moderately-to-Severely Active Ulcerative Colitis	15/07	CI
Health Care Up as Momentum Builds -- Health Care Roundup	13/07	DJ
UBS Raises Price Target on Pfizer to $30 From $28, Maintains Neutral Rating	12/07	MT
PFIZER INC : Receives a Buy rating from Goldman Sachs	12/07	ZD
Health Care Up as Obesity-Drug Wars Continue -- Health Care Roundup	12/07	DJ
Sector Update: Health Care Stocks Rise Late Afternoon	12/07	MT
PFIZER INC : Jefferies keeps its Buy rating	12/07	ZD
Sector Update: Health Care Stocks Advance in Afternoon Trading	11/07	MT
Top Midday Stories: Bain Capital to Acquire Envestnet; Delta, Pepsi Report Q2 Earnings; Pfizer Advances Development of Weight-Loss Pill; DOE Pledges $1.7 Billion for EV	11/07	MT
Sector Update: Health Care Stocks Advance Premarket Thursday	11/07	MT
Sector Update: Health Care	11/07	MT
CureVac Notes New Court Trial Timeline for Patent Cases Against Pfizer, BioNTech	11/07	MT
Pfizer: advances in anti-obesity pill danuglipron	11/07	CF
CureVac Provides Trial Dates for Patent Litigation Against Pfizer, BioNTech	11/07	MT
Exchange-Traded Funds, Equity Futures Edge Lower Pre-Bell Ahead of Key Inflation Data	11/07	MT
Pfizer to Advance Development of Modified-Release Formulation of Danuglipron	11/07	MT
Futures edge lower ahead of inflation test; Delta Airlines falls	11/07	RE
Pfizer Picks Once-Daily Obesity Pill Version for Further Study	11/07	DJ
Pfizer moves forward with once-daily weight loss drug	11/07	RE
Pfizer Advances Development of Once-Daily Formulation of Oral GLP-1 Receptor Agonist Danuglipron	11/07	CI
Pfizer: collaboration agreement with Evotec in France	10/07	CF
Barclays Adjusts Pfizer's Price Target to $30 From $28	10/07	MT
Sector Update: Health Care Stocks Steady Premarket Wednesday	10/07	MT
Evotec, Pfizer Enter Research Collaboration on Metabolic, Infectious Diseases	10/07	MT
Evotec, Pfizer Team Up for Early Drug Discovery for Metabolic, infectious Diseases	10/07	MT

Chart Pfizer, Inc.

Duration

Period

More charts

Company Profile

Pfizer, Inc. is the world's leading pharmaceutical group. Net sales break down by family of products as follows: - primary care products (72.8%): medicines used in internal medicine, vaccines, medicines for the prevention and treatment of Covid-19, antivirals, mRNA-based products, etc.; - specialty care products (13.8%): medicines used in immunology, in hospitals and for the treatment of rare diseases, anti-inflammatory medicines, etc.; - oncology products (12.1%); - other (1.3%). At the end of 2022, the group had more than 35 manufacturing sites worldwide. Net sales are distributed geographically as follows: the United States (42.3%), Europe (21.9%) and other (35.8%).

Sector

Pharmaceuticals

Calendar

26/07/2024 - Détachement de

Related indices

S&P 500

More about the company

Income Statement Evolution

More financial data

Analysis / Opinion

Pfizer, Inc: A cycle for nothing?

December 14, 2023 at 09:28 pm IST

Albert Bourla, Pfizer CEO (full interview): mRNA, acquisitions, weight-loss drugs

October 01, 2023 at 02:20 am IST

More Strategies

Ratings for Pfizer, Inc.

Trading Rating

Investor Rating

ESG Refinitiv

C+

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

OUTPERFORM

Number of Analysts

Last Close Price

29.5 USD

Average target price

32.1 USD

Spread / Average Target

+8.80%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Pharmaceuticals

	1st Jan change	Capi.
PFIZER, INC.	+2.47%	17TCr
ELI LILLY AND COMPANY	+61.53%	85TCr
NOVO NORDISK A/S	+34.02%	63TCr
JOHNSON & JOHNSON	-3.66%	36TCr
MERCK & CO., INC.	+15.06%	32TCr
ABBVIE INC.	+9.18%	30TCr
ROCHE HOLDING AG	+11.41%	23TCr
NOVARTIS AG	+15.35%	23TCr
AMGEN INC.	+15.67%	18TCr
SANOFI	+1.87%	13TCr

Other Pharmaceuticals

Pfizer, Inc.

Equities

PFE

US7170811035

Pharmaceuticals

Pfizer : Dubai Steps Up Rollout Of The Pfizer Jab

EPS Revisions